Comparison of a soluble co-formulation of insulin degludec/insulin aspart vs biphasic insulin aspart 30 in type 2 diabetes: a randomised trial

Niskanen L., Leiter L. A., Franek E., Weng J., Damci T., Munoz-Torres M., ...Daha Fazla

EUROPEAN JOURNAL OF ENDOCRINOLOGY, cilt.167, sa.2, ss.287-294, 2012 (SCI-Expanded, Scopus) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 167 Sayı: 2
  • Basım Tarihi: 2012
  • Doi Numarası: 10.1530/eje-12-0293
  • Dergi Adı: EUROPEAN JOURNAL OF ENDOCRINOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.287-294
  • İstanbul Üniversitesi-Cerrahpaşa Adresli: Evet

Özet

Objective: Insulin degludec/insulin aspart (IDegAsp) is a soluble co-formulation of insulin degludec (70%) and insulin aspart (IAsp: 30%). Here, we compare the efficacy and safety of IDegAsp, an alternative IDegAsp formulation (AF: containing 45% IAsp), and biphasic IAsp 30 (BIAsp 30).